Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.

@article{Oken1996CompleteRI,
  title={Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.},
  author={Martin M. Oken and Robert A Kyle and Phillip R Greipp and Neil E Kay and Athanasios Tsiatis and Stephanie A. Gregory and R JSpiegel and M JO'Connell},
  journal={Leukemia & lymphoma},
  year={1996},
  volume={20 5-6},
  pages={447-52}
}
The purpose of this study was to evaluate a new regimen for the treatment of multiple myeloma based on alternating 3-week cycles of chemotherapy and interferon (rIFN alpha 2). In this prospective phase II clinical trial the Eastern Cooperative Oncology Group evaluated a regimen consisting of 2 cycles of VBMCP (Vincristine 1.2 mg/M(2) IV d1, BCNU 20 mg/M(2) IV d1, Melphalan 8 mg/M(2) PO dl-4, Cyclophosphamide 400 mg/M2 IV d1, Prednisone 40 mg/M(2) PO d1-7) followed by alternating 3-week cycles… CONTINUE READING

Similar Papers

Loading similar papers…